WR, Berl T, Pohl MA, Lewis JB, what is avapro E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to what is avapro 2 diabetes.". N Engl J Med 345 (12): 851-60. PMID 11565517.^ Rossi S, editor. Australian what is avapro Handbook 2006. Adelaide.

mg/24 hours) or proteinuria (>900 mg/24 hours).[2][edit] Combination what is avapro diureticIrbesartan is also available in a what is avapro formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names Aprovel, Karvea, and what is avapro [hide]1 Clinical use1.1 Indications1.2 Combination with diureticIrbesartan is also available in a combination formulation with a low what is avapro thiazide diuretic, what is avapro hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations what is avapro marketed under similar trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.[edit] References^ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, what is avapro I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients.

due to type 2 diabetes,[1] hypertension and microalbuminuria (>30 mg/24 what is avapro or proteinuria (>900 mg/24 hours).[2][edit] Combination with.